Human Papillomavirus (HPV) - Prophylaxis Landscape 2017 - Product Image

Human Papillomavirus (HPV) - Prophylaxis Landscape 2017

  • ID: 4330737
  • Report
  • 79 Pages
  • DelveInsight
1 of 5
Understand the Future Market Competition in the Global Human Papillomavirus (HPV) Vaccines Market and an Insightful Review of the Key Market Drivers and Barriers

FEATURED COMPANIES

  • Agilvax
  • EyeGene Inc.
  • GlaxoSmithKline
  • iBio Inc.
  • Merck & Co. Inc.
  • others
  • MORE

Human Papilloma Virus (HPV) - Prophylaxis Landscape 2017 report provides an overview of the Human Papilloma Virus (HPV) to understand the HPV Prophylaxis coverage for 7MM (United States, Germany, Spain, Italy, France and United Kingdom & Japan) and market size for 6 MM (excluding Japan).

As per our analysis a total of approximately 7.3 Million people were vaccinated with HPV Vaccines in 2016. US accounts for the highest number of population vaccinated for HPV infections in comparison to EU5 and Japan because of the better coverage of HPV Vaccines and better awareness in United States. Our analysts expect that the number of people getting vaccinated by HPV vaccines shall increase in the coming years due to the expected increase in the coverage of HPV Vaccines.

The HPV Prophylaxis market was estimated at 1.98 Billion in 2016 for 6MM. The U.S. has the major hold over HPV Prophylaxis market as it accounts for 90.5% of the revenue from the total 6 Major Market size. For now there are only three approved HPV Vaccines in Market.

This report provides an in-depth analysis on the HPV Vaccines covering pre-clinical and clinical studies and Collaborations details. The report also provides the HPV vaccines licensing opportunities, acquisitions, market drivers and barriers. It provides a comprehensive review of the market trends, key company profiles including its business and product developments.

Key Coverage and Benefits:

  • The report will help in developing business strategies by understanding the trends shaping and driving the global Human PapillomaVirus (HPV) Vaccines market
  • Organize sales and marketing efforts by identifying the best opportunities for Human PapillomaVirus (HPV) Vaccines in US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan
  • To understand the future market competition in the global Human PapillomaVirus (HPV) Vaccines market and Insightful review of the key market drivers and barriers
  • To understand the regulatory scenario in major markets
  • Overview of the global HPV Vaccines pipeline scenario, products and associated companies information
  • Coverage of global HPV Vaccines under development
  • Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
  • The report also covers the detailed global historical and forecasted Human Papilloma Virus (HPV) Vaccines market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) from 2015-2025
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Agilvax
  • EyeGene Inc.
  • GlaxoSmithKline
  • iBio Inc.
  • Merck & Co. Inc.
  • others
  • MORE

1. Key Coverage and Benefits of the Report

2. Executive Summary

3. Human PapillomaVirus (HPV) Vaccines Market Overview at a Glance
3.1. Total Market Share Distribution of Human Papilloma Virus (HPV) Vaccines for 6 MM in 2016
3.2. Total Market Share Distribution of Human Papilloma Virus (HPV) Vaccines for 6 MM in 2025

4. Human PapillomaVirus (HPV)
4.1. Categories of Human PapillomaVirus (HPV)
4.2. Causes
4.3. Cancers caused by HPV
4.4. The HPV vaccination
4.5. Mechanism of Action of HPV Vaccines

5. Summary of HPV Vaccine characteristics

6. HPV Infection and Cervical Cancer

7. Epidemiology and Patient Population

8. United States
8.1. Population with Human PapillomaVirus (HPV) Vaccination (2013-2025)in United States

9. Europe
9.1. Germany
9.1.1. Population with Human PapillomaVirus (HPV) Vaccination
9.2. France
9.2.1. Population with Human PapillomaVirus (HPV) Vaccination
9.3. United Kingdom
9.3.1. Population with Human PapillomaVirus (HPV) Vaccination in United Kingdom
9.4. Spain
9.4.1. Population with Human PapillomaVirus (HPV) Vaccination
9.5. Italy
9.5.1. Population with Human PapillomaVirus (HPV) Vaccination in Italy

10. Japan
10.1.1. Population with Human PapillomaVirus (HPV) Vaccination in Japan

11. HPV Prophylaxis
11.1. Mid Stage Products (Phase II)
11.1.1. Comparative Analysis
11.2. INO-3112: Inovio Pharmaceuticals, Inc.
11.2.1. Product Description
11.2.2. Research and Development
11.2.3. Product Development Activities
11.2.4. INO-3112
11.3. Early Stage Products (Phase I)
11.3.1. Comparative Analysis

12. CKD-12201: Chong Kun Dang Pharmaceutical Corp.
12.1. Product Description
12.2. Product Development Activities

13. EG-HPV: EyeGene, Inc.
13.1. Product Description
13.2. Research and Development
13.3. Product Development Activities

14. Pre-clinical Products
14.1. Comparative Analysis

15. iBiomodulator with the E7GGG or E7 antigens: iBio Inc.
15.1. Product Description
15.2. Research and Development
15.3. Product Development Activities

16. AX03: Agilvax
16.1. Product Description
16.2. Research and Development
16.3. Product Development Activities

17. HPV Vaccine: Soligenix
17.1. Product Description
17.2. Research and Development
17.3. HPV Vaccine

18. Marketed Vaccines
18.1. Cervarix: GlaxoSmithKline
18.2. Gardasil/ Gardasil 9: Merck & Co., Inc.

19. Gardasil Story

20. HPV Vaccine Key Players

21. Global Human PapillomaVirus (HPV) Vaccines: Country-Wise Market Analysis
21.1. Region-Specific Market Distribution and Comparison
21.2. Overview on Total Human PapillomaVirus (HPV) Vaccines Market (2016)
21.3. Overview on Total Human PapillomaVirus (HPV) Vaccines Market (2025)

22. Global Human Papilloma Virus (HPV) Vaccines: Market Analysis
22.1. United States Market Size

23. Europe
23.1. Germany Market Size
23.2. France Market Size
23.3. United Kingdom Market Size
23.4. Spain Market Size
23.5. Italy Market Size
23.6. Japan Market Size
23.6.1. Ongoing Steps to Encourge the HPV Vaccine recommendation in Japan

24. Rest of World (RoW) Scenario

25. Additional Information
25.1. Future Goals of HPV Vaccination
25.1.1. HPV Vaccination in Asia:
25.1.2. HPV Vaccination in Australia:
25.1.3. HPV Vaccination in Latin America:
25.1.4. HPV Vaccination in Middle-East and North-Africa:

26. Market Barriers

27. Market Drivers

28. Unmet Needs

29. SWOT Analysis

30. Appendix

31. Report Methodology

32. Consulting Services

33. Disclaimer

34. About

List of Tables
Table 1: 6 Major Market and ROW Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million (2013-2025)
Table 2: Summary of HPV vaccine characteristics
Table 3: Population with Human PapillomaVirus (HPV) Vaccination in United States(2013-2025)
Table 4: Population with Human PapillomaVirus (HPV) Vaccination in Germany (2013-2025)
Table 5: Population with Human PapillomaVirus (HPV) Vaccination in France (2013-2025)
Table 6: Population with Human PapillomaVirus (HPV) Vaccination in United Kingdom (2013-2025)
Table 7: Population with Human PapillomaVirus (HPV) Vaccination in Spain (2013-2025)
Table 8: Population with Human PapillomaVirus (HPV) Vaccination in Italy (2013-2025)
Table 9: Population with Human PapillomaVirus (HPV) Vaccination in Japan (2013-2025)
Table 10: Mid Stage Products (Phase II)
Table 11: Early Stage Products (Phase I)
Table 12: Pre-clinical Products
Table 13: Gardasil/Gardasil 9 Global Sales for Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Table 14: Region specific market distribution and comparison
Table 15: Total Human PapillomaVirus (HPV) Vaccines Market Size (2016) - 6MM
Table 16: Total Human PapillomaVirus (HPV) Vaccines,Market Size(2025) as per the 6MM
Table 17: United States Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Table 18: Germany Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Table 19: France Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Table 20: United Kingdom Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Table 21: Spain Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Table 22: Italy Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)

List of Figures
Figure 1: 6 Major Market and ROW Market Size of Human Papilloma Virus (HPV) Vaccines in USD Million (2013-2025)
Figure 2: Three-Dimensional Model of Human PapillomaVirus (HPV)
Figure 3: Programmatic interventions to prevent HPV infections and cervical cancer
Figure 4: Population with Human PapillomaVirus (HPV) Vaccination in United States(2013-2025)
Figure 5: Population with Human PapillomaVirus (HPV) Vaccination in Germany (2013-2025)
Figure 6: Population with Human PapillomaVirus (HPV) Vaccination in France (2013-2025)
Figure 7: Population with Human PapillomaVirus (HPV) Vaccination in United Kingdom(2013-2025)
Figure 8: Population with Human PapillomaVirus (HPV) Vaccination in Spain (2013-2025)
Figure 9: Population with Human PapillomaVirus (HPV) Vaccination in Italy (2013-2025)
Figure 10: Population with Human PapillomaVirus (HPV) Vaccination in Japan (2013-2025)
Figure 11: Mid Stage Products (Phase II)
Figure 12: Early Stage Products (Phase I)
Figure 13: Pre-clinical Products
Figure 14: Gardasil/Gardasil 9 Global Sales for Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Figure 15: Region-specific market distribution and comparison
Figure 16: Total 6 Major Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2016)
Figure 17: Total 6 Major Market Size of Human PapillomaVirus (HPV) Vaccines in USD Millions, (2025)
Figure 18: United States Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Figure 19: Germany Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Figure 20: France Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Figure 21: United Kingdom Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)
Figure 22: Spain Market Size of Human PapillomaVirus (HPV) Vaccines in USD Million, (2013-2025)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Agilvax
  • Chong Kun Dang Pharmaceutical Corp
  • EyeGene Inc.
  • GlaxoSmithKline
  • iBio Inc.
  • Inovio Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Soligenix
  • others
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll